Solve any doubts you might have with these Covid ANTIBODY Test kit FAQs

ANTIBODYCOVID is the only antigen antibody test that measures the three specific levels of the most important immunoglobulin for the body’s immunisation against COVID. That’s why this test works and it’s the most accurate and reliable test on the market. The extremely accurate ANTIBODY Covid-19 test measures the number of antibodies you have with the greatest accuracy, establishing your level of protection against COVID-19 with only a blood sample needed.

COVID-19 is an infectious disease caused by a virus, a coronavirus that was only recently discovered. For most people who get COVID-19 the symptoms of the virus are those of a light to moderate respiratory illness and most people recover without needing any special treatment. Older people or people with underlying health problems are more likely to develop a serious illness.

(IgG1 +, IgA +, IgM +) – A positive result for any of the three immunoglobulins indicates that there are antibodies against SARS CoV-2 protein S in the sample and therefore that you have been infected with this virus in any of its variants (symptomatically or asymptomatically), or that you have been vaccinated and that you have potentially protective antibodies in your blood.

(IgG1-, IgA-, IgM-) – A negative result for all three immunoglobulins indicates that there are NO antibodies against SARS-CoV-2 protein S in the sample and therefore that you have NOT passed the infection with this virus in any of its variants, or that the infection or vaccination (in the case of been vaccinated) have not generated sufficient humoral immunity to be detected by this technique.

(IgG1 +, IgA +, IgM-) – A positive result for IgG1 and IgA but negative for IgM would indicate that you were infected with the virus or were vaccinated a long time ago and that you have potentially protective antibodies in your blood. A presence of IgA anti-S would indicate that you possibly have this type of antibody in the mucous membranes of the respiratory system and that you have a first protective barrier against infection.

(IgG1 +, IgA-, IgM-). – A positive result for IgG1 but negative for IgA and IgM would indicate that you were infected with the virus or were vaccinated and that you have potentially protective antibodies in your blood.

(IgG1-, IgA-, IgM +) -If you have antibodies of the IgM type and not IgG1 or IgA, you are probably passing the infection, have had it very recently or have recently been vaccinated. If it had been more than a month since the infection or since the second dose of the vaccine and you have IgM but not IgG1 or IgA, these results would indicate that your immunity is not complete.

(IgG1-, IgA + IgM-) – If you have antibodies of the IgA type and not IgG1 or IgM, you are probably passing the infection, have had it very recently or have been vaccinated recently. If it had been more than a month since the infection or since the second dose of the vaccine and you had IgA but not IgG1 or IgM, these results would indicate that your immunity is not complete.

Positive: the test result is compatible with the presence of IgG1, IgM and/or IgA antibodies against the Spike protein (protein S) from SARS-CoV-2 in the sample tested.

Negative: the test result is compatible with the absence of IgG1, IgM and/or IgA antibodies against the Spike protein (protein S) from SARS-CoV-2 in the sample tested.

Ratio: This value quantifies the amount of immunoglobulin of each type (if detectable) in arbitrary units of measure. The positivity ranges for each immunoglobulin are expressed in parentheses. In the case of IgG1, it is indicated if the value is low (0.001-3 AMU), medium (3.001-5 AUM), high (5.001-10 AMU) or very high (more than 10 AMU).

IgG1 is the most abundant form of IgG in serum. It is a very important immunoglobulin in mediating antibody responses against viral infections. It has neutralising capacity against SARS-CoV-2 (ability to bind complement and also to bind with high affinity to Fc receptors on immune system cells such as macrophages and NK cells) and can activate the destruction of virus-infected cells. IgA is an immunoglobulin found in abundance in the mucosal lining fluids of the nose, pharynx, bronchi and lungs, making it a first barrier in the neutralisation of viruses entering via the airborne route. IgM provides the first protection in response to infection. It is able to activate the destruction of infected cells, however, it is a low affinity immunoglobulin, i.e. it does not bind very strongly to viruses and is weak in its neutralising capacity.

This technology makes useof cultured cells known as Jurkat, which have been genetically modified toproduce the complete SARS CoV 2 spike protein, so that this viral protein, against which the most clinically relevant antibodies are produced during infection or vaccination, is “displayed” in its native form (in the form of trimers) on the surface of these cells. It has major advantages over other serological methods such as ELISA or rapid antibody tests that make use of protein S fragments (instead of the whole protein), as well as simpler technologies, resulting in lower sensitivity and specificity.
The test makes it possible to measure the resulting immune response after vaccination and to check that the vaccination has worked properly, as none of the vaccines currently administered is 100% efficient.
IgG1 is the most abundant form of IgG in serum. It is a very important immunoglobulin in mediating antibody responses against viral infections. It is a neutralising immunoglobulin against SARS-CoV-2, which means that it defends the body by neutralising any effect the infectious particle has biologically. IgM is the first immunoglobulin produced in response to an infection: it offers the first protection. However, it is a low affinity immunoglobulin, i.e. it does not bind very strongly to viruses and is weak in its neutralising capacity. IgG2 plays an important role in neutralising toxins produced by bacteria. IgG3, despite being a neutralising immunoglobulin against SARS-CoV-2, is short-lived in the blood: in about 7 days half of its antibodies disappear. IgG4 is the least abundant IgG in human serum. It is thought to have more of an anti-inflammatory effect than a killing effect on virus-infected cells.
As a mucosa-targeted virus, SARS-CoV-2 can induce strong mucosal immunity, leading to the generation of IgA. The IgA system not only serves as a first-line barrier to prevent pathogens from attaching to the mucosa, but also interacts with the innate and adaptive immune systems for the maintenance of homeostasis. Studies of IgA antibody levels to SARS CoV-2 in sera from post COVID patients have found that IgA and IgG levels were markedly higher in patients with severe disease compared to patients with mild or moderate disease.
The JFCI flow cytometry technique has been found to be 10 times more sensitive than conventional serological techniques such as CLIA or ELISA. This is the reason why more positive samples are detected than by other commercial CLIA or ELISA kits. In internal in vitro studies, comparing this technique with other commercial antibody detection kits by CLIA or ELISA, we have found that these were not able to detect samples that were clearly positive by JFCI, and it was corroborated by “in vitro” assays that they were all true positives, as they had neutralising antibodies against SARS-COV2 (data not yet published).
Testing the antibodies produced against the whole protein allows a wider range of antibodies to be detected than if only a part is used. In addition, it allows the detection of antibodies against different variants of the virus to be covered.
A positive result means that you have developed neutralising antibodies against the S protein of the SARS-CoV-2 virus. Our report will also provide you with a numerical value of these antibodies with a reference range in arbitrary units that can be used for further follow-up studies of your antibody level. This test will detect antibodies both in people who have been naturally infected by the virus and in those who have received a vaccine against the virus. Although it is a quantitative test and is detecting neutralising antibodies, there are insufficient studies to predict the level of protection against SARS-CoV-2 virus in an individual in whom antibodies have been detected by this method. A negative result indicates that the individual has probably not been exposed to SARS-CoV-2 or that the level of antibodies present is not sufficient for detection by this technique.
It means that you have been in contact with SARS-CoV-2 or have been vaccinated against SARS-CoV-2, but it is not a valid test for the diagnosis of SARS-CoV-2 infection.
It means that the individual has not been in contact with the SARS CoV-2 virus and has not been vaccinated, or has not developed antibodies to the virus or the vaccine at levels sufficient to be detected by this test. It cannot be excluded that the individual has other immune protective mechanisms than antibody production
Although information on the importance of different immunoglobulins in COVID-19 disease is limited, serological tests using a combination of antibodies could be a way to improve accuracy in establishing the degree of immunity, as well as to monitor the evolution of acquired immunity after vaccination by measuring the levels and subtypes of antibodies that persist in periodic analyses.
If you currently have the symptoms of a COVID-19 infection you should stay at home in isolation, and you can request an antigen or PCR test. If you think you might have had COVID-19 (at least 21 days ago) or you were in contact in the past with someone who had the virus, you can use the antibody test to see if you were infected. Even if you didn’t have any symptoms at the time it’s worth having an antibody test as it has been shown that four out of every five people with COVID-19 have no symptoms.
The flow cytometry analysis method is used to measure the levels of immunoglobulins providing protection against SARS-CoV-2. The full-length virus spike protein is analysed, which makes the test almost 99% accurate.
The test is almost 99% accurate, so there’s little chance of a false positive. However, you could get a false negative result if you have the test too soon after a possible infection. The antibodies the test detects only start to develop 14 – 21 days after the initial infection, so if you have the test before this you could get a false negative result.

(IgG1 +, IgA +, IgM +) – A positive result for any of the three immunoglobulins indicates that there are antibodies against SARS-CoV-2 protein S in the sample and therefore that you have been infected with this virus in any of its variants (symptomatically or asymptomatically), or that you have been vaccinated and that you have potentially protective antibodies in your blood.

(IgG1-, IgA-, IgM-) – A negative result for all three immunoglobulins indicates that there are NO antibodies against SARS-CoV-2 protein S in the sample and therefore that you have NOT passed the infection with this virus in any of its variants, or that the infection or vaccination (in the case of been vaccinated) have not generated sufficient humoral immunity to be detected by this technique.

(IgG1 +, IgA +, IgM-) – A positive result for IgG1 and IgA but negative for IgM would indicate that you were infected with the virus or were vaccinated a long time ago and that you have potentially protective antibodies in your blood. A presence of IgA anti-S would indicate that you possibly have this type of antibody in the mucous membranes of the respiratory system and that you have a first protective barrier against infection.

(IgG1 +, IgA-, IgM-) – A positive result for IgG1 but negative for IgA and IgM would indicate that you were infected with the virus or were vaccinated and that you have potentially protective antibodies in your blood.

(IgG1-, IgA-, IgM +) -If you have antibodies of the IgM type and not IgG1 or IgA, you are probably passing the infection, have had it very recently or have recently been vaccinated. If it had been more than a month since the infection or since the second dose of the vaccine and you have IgM but not IgG1 or IgA, these results would indicate that your immunity is not complete.

(IgG1-, IgA + IgM-) – If you have antibodies of the IgA type and not IgG1 or IgM, you are probably passing the infection, have had it very recently or have been vaccinated recently. If it had been more than a month since the infection or since the second dose of the vaccine and you had IgA but not IgG1 or IgM, these results would indicate that your immunity is not complete.